Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GILD
  • CUSIP: 37555810
  • Web: www.gilead.com
Capitalization:
  • Market Cap: $92.15045 billion
  • Outstanding Shares: 1,306,728,000
Average Prices:
  • 50 Day Moving Avg: $65.46
  • 200 Day Moving Avg: $69.00
  • 52 Week Range: $63.76 - $88.85
P/E:
  • Trailing P/E Ratio: 7.53
  • Foreward P/E Ratio: 9.61
  • P/E Growth: -1.25
Sales & Book Value:
  • Annual Revenue: $29.1 billion
  • Price / Sales: 3.20
  • Book Value: $15.64 per share
  • Price / Book: 4.55
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 3.0%
Profitability:
  • EBIDTA: $18.24 billion
  • Net Margins: 43.42%
  • Return on Equity: 76.64%
  • Return on Assets: 25.55%
Debt:
  • Debt-to-Equity Ratio: 1.26%
  • Current Ratio: 2.59%
  • Quick Ratio: 2.41%
Misc:
  • Average Volume: 7.62 million shs.
  • Beta: 1.2
  • Short Ratio: 1.45
 

Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, May 2nd. Shareholders of record on Friday, June 16th will be paid a dividend of $0.52 per share on Thursday, June 29th. This represents a $2.08 annualized dividend and a yield of 2.92%. The ex-dividend date is Wednesday, June 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its earnings results on Tuesday, May, 2nd. The company reported $2.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.18 by $0.02. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. View Gilead Sciences' Earnings History.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

26 analysts have issued 12 month price objectives for Gilead Sciences' shares. Their forecasts range from $65.50 to $100.00. On average, they expect Gilead Sciences' share price to reach $80.99 in the next twelve months. View Analyst Ratings for Gilead Sciences.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. According to Zacks Investment Research, "Although Gilead’s first-quarter results beat on earnings, revenues missed expectations. The HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens which now represent 42% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. However, the HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales. The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year-over-year decrease." (5/5/2017)
  • 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
  • 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)
  • 5. Needham & Company LLC analysts commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD." (2/8/2017)

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

  • John C. Martin Ph.D., Executive Chairman of the Board
  • John F. Milligan Ph.D., Chief Executive Officer, Director
  • Robin L. Washington, Chief Financial Officer, Executive Vice President
  • Kevin B. Young, Chief Operating Officer
  • Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
  • Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
  • James R. Meyers, Executive Vice President - Worldwide Commercial Operations
  • John F. Cogan Jr. Ph.D., Lead Independent Director
  • Kelly A. Kramer, Independent Director
  • Kevin E. Lofton, Independent Director

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.88%), Vanguard Group Inc. (6.94%), State Street Corp (4.59%), Bank of New York Mellon Corp (2.34%), FMR LLC (1.74%) and Parnassus Investments CA (1.28%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Canada Pension Plan Investment Board, NN Investment Partners Holdings N.V., Westfield Capital Management Co. LP, Parametric Portfolio Associates LLC, Waverton Investment Management Ltd, Morgan Stanley and Pioneer Investment Management Inc.. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Parnassus Investments CA, Bank of New York Mellon Corp, Renaissance Technologies LLC, Platinum Investment Management Ltd., Los Angeles Capital Management & Equity Research Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $71.24.


MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  1,479 (Vote Outperform)
Underperform Votes:  464 (Vote Underperform)
Total Votes:  1,943
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Hold Ratings, 15 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.65)
Consensus Price Target: $80.99 (13.69% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/23/2017Deutsche Bank AGInitiated CoverageBuy$79.00LowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
6/16/2017William BlairReiterated RatingOutperformLowView Rating Details
5/15/2017Credit Suisse GroupReiterated RatingOutperform$79.00N/AView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Barclays PLCReiterated RatingOverweight$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
5/3/2017Robert W. BairdReiterated RatingOutperform$87.00MediumView Rating Details
5/3/2017Maxim GroupReiterated RatingHoldLowView Rating Details
5/3/2017BMO Capital MarketsReiterated RatingHold$75.00 -> $76.00LowView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
4/17/2017Cowen and CompanyReiterated RatingBuy$100.00LowView Rating Details
4/6/2017Jefferies Group LLCReiterated RatingBuy$82.00LowView Rating Details
4/6/2017J P Morgan Chase & CoReiterated RatingOverweight$82.00LowView Rating Details
3/13/2017Bank of America CorporationReiterated RatingNeutral$76.00 -> $68.19LowView Rating Details
3/13/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
3/1/2017MizuhoLower Price TargetBuy$88.00 -> $77.00N/AView Rating Details
2/14/2017Berenberg BankSet Price TargetBuy$112.00 -> $78.00N/AView Rating Details
2/8/2017Royal Bank Of CanadaLower Price Target$75.00N/AView Rating Details
2/8/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/8/2017Citigroup Inc.DowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
2/8/2017Morgan StanleyLower Price TargetEqual Weight$85.00 -> $77.00N/AView Rating Details
2/8/2017Wells Fargo & CompanyReiterated RatingMarket Perform$79.50 -> $65.50N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
5/4/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$120.00 -> $116.00N/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00N/AView Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00N/AView Rating Details
(Data available from 6/27/2015 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)
Earnings History by Quarter for Gilead Sciences (NASDAQ GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
2017 EPS Consensus Estimate: $8.09
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.09$2.42$2.23
Q2 20173$2.01$2.17$2.08
Q3 20173$1.88$2.02$1.93
Q4 20173$1.79$1.94$1.85
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Next Dividend:6/29/2017
Annual Dividend:$2.08
Dividend Yield:2.92%
Payout Ratio:21.99% (Trailing 12 Months of Earnings)
26.46% (Based on This Year's Estimates)
28.07% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History by Quarter for Gilead Sciences (NASDAQ GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2017quarterly$0.523.09%6/14/20176/16/20176/29/2017
2/7/2017quarterly$0.523.11%3/14/20173/16/20173/30/2017
11/1/2016quarterly$0.472.59%12/13/201612/15/201612/29/2016
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 73.99%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.75View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.94View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Gilead Sciences (NASDAQ:GILD)
Latest Headlines for Gilead Sciences (NASDAQ:GILD)
Source:
DateHeadline
americanbankingnews.com logoVetr Inc. Upgrades Gilead Sciences, Inc. (GILD) to Strong-Buy
www.americanbankingnews.com - June 27 at 12:34 AM
finance.yahoo.com logoFeatured Company News - Gilead's Vosevi Receives Positive Opinion from European CHMP; Set to Deliver Advanced Treatment for All HCV Genotypes
finance.yahoo.com - June 26 at 9:33 AM
finance.yahoo.com logo[$$] Gilead Is Finally a Buy: 'Value Trap No More'
finance.yahoo.com - June 24 at 10:44 PM
americanbankingnews.com logoGilead Sciences Sees Unusually Large Options Volume (GILD)
www.americanbankingnews.com - June 24 at 7:02 AM
seekingalpha.com logoGilead: Is Sentiment Changing? - Seeking Alpha
seekingalpha.com - June 24 at 6:26 AM
seekingalpha.com logoGilead: The Conundrum - Seeking Alpha
seekingalpha.com - June 23 at 3:29 PM
seekingalpha.com logoGilead: How Sweet It Is - Seeking Alpha
seekingalpha.com - June 23 at 3:29 PM
finance.yahoo.com logoEuropean CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
finance.yahoo.com - June 23 at 3:29 PM
finance.yahoo.com logoDeutsche Bank's Take On Big Pharma: 3 Buys And A Hold
finance.yahoo.com - June 23 at 3:29 PM
finance.yahoo.com logoWhy Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout
finance.yahoo.com - June 23 at 3:29 PM
finance.yahoo.com logoGilead: The Worst is Over?
finance.yahoo.com - June 23 at 3:29 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Receives New Coverage from Analysts at Deutsche Bank AG
www.americanbankingnews.com - June 23 at 12:12 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Upgraded at BidaskClub
www.americanbankingnews.com - June 23 at 12:58 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Given Market Perform Rating at Leerink Swann
www.americanbankingnews.com - June 22 at 11:04 PM
finance.yahoo.com logoIs Gilead Sciences on the Verge of a Powerful Rally?
finance.yahoo.com - June 22 at 9:29 AM
finance.yahoo.com logoGilead Sciences, Inc. breached its 50 day moving average in a Bullish Manner : GILD-US : June 22, 2017
finance.yahoo.com - June 22 at 9:29 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Cut to "Buy" at Vetr Inc.
www.americanbankingnews.com - June 22 at 12:34 AM
thestreet.com logoIs Gilead Sciences on the Verge of a Powerful Rally Leg? - TheStreet.com
www.thestreet.com - June 21 at 7:02 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Expected to Post Quarterly Sales of $6.25 Billion
www.americanbankingnews.com - June 21 at 9:36 AM
zacks.com logoGilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada
www.zacks.com - June 20 at 6:10 PM
finance.yahoo.com logoBig Money Flowing Into Biotech Stocks - Again
finance.yahoo.com - June 20 at 6:10 PM
finance.yahoo.com logoGilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada
finance.yahoo.com - June 20 at 6:10 PM
finance.yahoo.com logoWhy This Billionaire Just Bought Gilead Sciences, Synergy, and Valeant Stock
finance.yahoo.com - June 20 at 6:10 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Expected to Post Earnings of $2.04 Per Share
www.americanbankingnews.com - June 19 at 6:46 PM
americanbankingnews.com logoStock Traders Purchase High Volume of Gilead Sciences Call Options (GILD)
www.americanbankingnews.com - June 19 at 5:38 PM
finance.yahoo.com logoETFs with exposure to Gilead Sciences, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 4:19 PM
finance.yahoo.com logoGilead Receives Approval in Canada for VEMLIDY™ (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
finance.yahoo.com - June 19 at 12:57 PM
finance.yahoo.com logoJames Flynn Plays Two Key Biotech Stocks: Valeant Pharmaceuticals Intl Inc (VRX), Gilead Sciences, Inc. (GILD)
finance.yahoo.com - June 19 at 12:57 PM
finance.yahoo.com logo5 Answers to Questions Gilead Sciences' Investors Probably Have
finance.yahoo.com - June 18 at 5:05 PM
fool.com logo5 Answers to Questions Gilead Sciences' Investors Probably Have
www.fool.com - June 18 at 12:23 PM
finance.yahoo.com logoIs Gilead Sciences a Great Stock for Value Investors?
finance.yahoo.com - June 16 at 6:12 PM
finance.yahoo.com logoGilead Sciences, Inc. : GILD-US: Dividend Analysis : June 16th, 2017 (record date) : By the numbers : June 16, 2017
finance.yahoo.com - June 16 at 6:12 PM
americanbankingnews.com logoGilead Sciences' (GILD) Outperform Rating Reaffirmed at William Blair
www.americanbankingnews.com - June 16 at 2:26 PM
finance.yahoo.com logoNew Data Shows TG Therapeutics Could Be Onto Something Big
finance.yahoo.com - June 15 at 7:36 PM
seekingalpha.com logoEvaluating Gilead's Deep Value Bull Case - Seeking Alpha
seekingalpha.com - June 14 at 6:43 PM
seekingalpha.com logoGilead Sciences Is A Buy - Seeking Alpha
seekingalpha.com - June 14 at 12:03 PM
seekingalpha.com logoGilead's Oncology Pipeline: An Assessment - Seeking Alpha
seekingalpha.com - June 14 at 12:03 PM
nasdaq.com logoGilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2017 - Nasdaq
www.nasdaq.com - June 14 at 12:03 PM
finance.yahoo.com logoGilead (GILD) Submits NDA for HIV Combination Therapy Regimen
finance.yahoo.com - June 13 at 10:16 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 13 at 12:50 PM
streetinsider.com logoGilead Sciences (GILD) Submits NDA for Bictegravir, Emtricitabine and Tenofovir Alafenamide HIV Combo
www.streetinsider.com - June 12 at 6:15 PM
finance.yahoo.com logoGilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
finance.yahoo.com - June 12 at 6:15 PM
finance.yahoo.com logoBillionaire Israel ‘Izzy’ Englander Bets on Three Biotech Stocks: Valeant Pharmaceuticals Intl Inc (VRX), Gilead Sciences, Inc. (GILD), Synergy Pharmaceuticals Inc (SGYP)
finance.yahoo.com - June 12 at 6:15 PM
fool.com logo3 Beaten-Up Biotech Stocks: Are They Bargains?
www.fool.com - June 12 at 8:51 AM
seekingalpha.com logoFinally, Gilead Bottoms - Seeking Alpha
seekingalpha.com - June 10 at 5:29 PM
finance.yahoo.com logoETFs with exposure to Gilead Sciences, Inc. : June 9, 2017
finance.yahoo.com - June 9 at 5:51 PM
finance.yahoo.com logoGilead Sciences, Inc. :GILD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 8, 2017
finance.yahoo.com - June 8 at 6:25 PM
finance.yahoo.com logoSpring Bank Pharmaceuticals' Hepatitis B Results in Context
finance.yahoo.com - June 7 at 4:56 PM
finance.yahoo.com logo3 Value Stocks Perfect for Retirement
finance.yahoo.com - June 6 at 5:53 PM
fool.com logoWhy Gilead Sciences Stock Slumped in May
www.fool.com - June 6 at 8:49 AM

Social

Chart

Gilead Sciences (GILD) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by MarketBeat.com Staff